Section 01
What it's used for
Speeds Tendon Healing in Rats
In preclinical (animal) studies, BPC-157 sped healing of cut tendons and ligaments. In rat Achilles tendon studies, it improved function, tissue structure, and healing at the tendon-to-bone junction, and boosted new blood vessel growth.
▸Clinical wording
BPC-157 substantially accelerates healing of transected tendons and ligaments in preclinical models. In rat Achilles tendon transection studies, it improves functional recovery, biomechanical properties, collagen organization, and histological appearance. It promotes healing of the challenging tendon-to-bone interface (enthesis) and enhances medial collateral ligament (MCL) repair. Effects are mediated through FAK-paxillin-driven fibroblast migration, GHR upregulation, and enhanced angiogenesis.
Speeds Skin Wound Healing
In animal studies, BPC-157 sped skin wound healing: more new skin growth, tissue repair, and blood vessel growth. It worked even with diabetes, steroid-impaired healing, and poor blood flow, beating growth factor PDGF-BB in diabetic wounds.
▸Clinical wording
Accelerates cutaneous wound healing including enhanced re-epithelialization, granulation tissue formation, collagen organization, and increased vascular density. Effective even in compromised healing states: diabetic wounds, corticosteroid-impaired healing, and ischemic conditions. BPC-157 outperforms PDGF-BB in early collagen organization in diabetic wound models.
Bone Healing, With Key Gaps
In animal models, BPC-157 reduced bone loss and inflammation in gum disease, aided tendon-to-bone healing after Achilles injury even with steroids, and helped rabbit bone-defect healing. No study covered fracture healing or hip bone death.
▸Clinical wording
In animal models, BPC-157 reduces alveolar bone loss and inflammation in experimental periodontitis and promotes tendon-to-bone healing after Achilles tendon detachment, including when healing is impaired by corticosteroids. It also shows an osteogenic effect on healing of segmental bone defects in rabbits, with effects linked to angiogenesis and osteoblast stimulation. No dedicated study of BPC-157 in femoral fracture healing (callus formation, mineralization, mechanical strength) or in femoral head osteonecrosis (avascular necrosis) was found, so these specific claims are not supported.
Muscle Repair in Rat Studies
In rat studies, BPC-157 improved recovery after muscle crush injury and full cuts through the thigh muscle, restoring function that would otherwise stay permanently impaired. It helped tendon-muscle junction injuries, even with steroids.
▸Clinical wording
In rat models, BPC-157 enhances recovery after acute muscle crush injury and complete quadriceps muscle transection, restoring functional continuity that would otherwise leave a permanent deficit. It also promotes healing of myotendinous junction injuries and counteracts impaired muscle healing caused by systemic corticosteroid treatment. No study was found supporting effects on denervation-induced atrophy or satellite cell proliferation, so these claims are not included here.
Gut Protection in Animal Studies
In rodent studies, BPC-157 protected the stomach lining from NSAID, alcohol, and stress damage, and helped heal colitis- and Crohn's-like gut inflammation. As PL 14736, it reached human Phase II colitis trials, with no published results.
▸Clinical wording
In rodent models, BPC-157 protects gastric mucosa against NSAID-, alcohol-, and stress-induced lesions, and promotes healing in models of ulcerative-colitis-like and Crohn's-like intestinal inflammation, while counteracting intestinal barrier dysfunction. Under the designation PL 14736, review literature describes BPC-157 as having entered Phase II clinical trials for ulcerative colitis and being reported safe, but no published trial results demonstrating clinical efficacy were found. These gastrointestinal protective effects are therefore established in animal models, with human efficacy data still unpublished.
Nerve Protection in Animal Models
In animal models, BPC-157 showed protective effects after brain injury, spinal cord injury, and nerve damage. It affects brain chemical systems (dopamine, serotonin, GABA, opioid) and showed potential in Parkinson's disease models.
▸Clinical wording
Demonstrates protective effects in models of traumatic brain injury, spinal cord injury, and peripheral nerve damage. Modulates dopamine, serotonin, GABAergic, and opioid neurotransmitter systems. Counteracts dopaminergic neurotoxicity and shows potential in Parkinson's disease models.
Heart Protection in Animal Models
In animal models, BPC-157 protected against blood clots, heart attack, irregular heartbeat, and heart failure. It affected clotting cells (platelets) both ways, raising clotting when blood was too thin and lowering it when too thick.
▸Clinical wording
Protective effects in models of acute thrombosis, myocardial infarction, arrhythmias, and heart failure. Modulates hemostatic function with bidirectional effects on platelet aggregation — promoting aggregation when hypocoagulable and inhibiting it when hypercoagulable.
Liver Protection in Animal Studies
In animal studies, BPC-157 protected the liver from blocked liver arteries or bile ducts, and from the toxin carbon tetrachloride. It lowered liver-damage markers ALT, AST, and bilirubin, and countered alcohol-related damage.
▸Clinical wording
Protects liver against damage from hepatic artery ligation, bile duct ligation, and carbon tetrachloride. Reduces ALT, AST, and bilirubin levels. Counteracts alcohol-induced liver damage.
Section 02
Mechanism of Action
BPC-157 exerts its biological effects through activation of multiple interconnected molecular pathways that function synergistically to promote tissue repair, protect cells from damage, and maintain vascular integrity.
New blood vessels in damaged tissue
- The peptide switches on a receptor on blood-vessel cells that starts new capillaries growing.
- More nitric oxide in the vessel wall widens vessels and helps lining cells multiply.
- It also keeps that receptor signalling longer by changing how the receptor is recycled.
- In cell and chick-embryo assays, vessel formation rose 129-152% and tube formation 119-147%.
▸Clinical wording
VEGFR2-Akt-eNOS Angiogenic Pathway
The primary healing mechanism involves activation of vascular endothelial growth factor receptor 2 (VEGFR2), triggering phosphorylation of protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS). This cascade increases nitric oxide (NO) production in blood vessel walls, promoting vasodilation, endothelial cell proliferation, and new capillary formation (angiogenesis). BPC-157 additionally modulates VEGFR2 receptor internalization through Src kinase and caveolin-1 phosphorylation, resulting in sustained NO production. In vitro studies show 129–152% increases in blood vessel formation (CAM assays) and 119–147% increases in tube formation (HUVEC assays).
Helping cells grip and crawl
- The peptide strengthens, dose-dependently, the anchor points cells use to grip surfaces and move.
- In tendon cells this appeared as more migration, greater spreading and tidier internal fibres.
- The same cells were protected against damage from oxidative stress.
▸Clinical wording
FAK-Paxillin Pathway
BPC-157 dose-dependently increases phosphorylation of focal adhesion kinase (FAK) and paxillin, enhancing focal adhesion complex assembly critical for cell migration and tissue integration. In tendon fibroblasts, this manifests as enhanced migration through transwell filters, increased cell spreading, improved stress fiber organization, and cytoprotection against oxidative stress (H₂O₂-induced damage).
Making cells more responsive to growth hormone
- The peptide activates a signalling enzyme and raises growth hormone receptor levels in cells.
- Gene screening found that receptor among the most strongly increased genes.
- More receptors let cells respond harder to circulating growth hormone during tendon, ligament and bone healing.
▸Clinical wording
JAK-2/STAT and Growth Hormone Receptor Signaling
The peptide activates Janus kinase 2 (JAK-2) in a time-dependent manner and distinctively upregulates growth hormone receptor (GHR) expression at both mRNA and protein levels. Gene expression microarray analysis identifies GHR as one of the most abundantly upregulated genes. This primes cells to respond more vigorously to circulating growth hormone, enhancing anabolic signaling particularly important for tendon, ligament, and bone healing.
A signal relay that drives repair genes
- The peptide activates a relay enzyme pair that switches on three gene-control proteins.
- One of them rises within fifteen minutes and controls growth factor, cytokine and matrix genes.
- Blocking this relay with drugs completely abolished the peptide's migration and blood-vessel effects.
▸Clinical wording
ERK1/2 MAPK Signaling
BPC-157 activates extracellular signal-regulated kinase (ERK) 1/2, which phosphorylates downstream transcription factors c-Fos, c-Jun, and early growth response gene-1 (EGR-1). EGR-1 upregulation occurs within 15 minutes and directly controls expression of genes encoding growth factors, cytokines, and extracellular matrix proteins. Pharmacological ERK1/2 blockade (MEK inhibitors) completely abolishes BPC-157's pro-migratory and pro-angiogenic effects, confirming this pathway's essential role.
Two-way tuning of a signalling gas
- The peptide raises nitric oxide when it is too low and lowers it when pathologically high.
- It suppresses the inflammatory form of the producing enzyme while keeping the vessel-lining form.
- It couples this with counteracting free radicals, preventing formation of a damaging by-product.
▸Clinical wording
Nitric Oxide System Modulation
Unlike conventional NO modulators, BPC-157 exhibits bidirectional, context-dependent effects — increasing NO when levels are inappropriately low and decreasing it when pathologically elevated. It suppresses inducible NOS (iNOS) expression while maintaining or enhancing endothelial NOS (eNOS), shifting NO production toward homeostatic signaling. Critically, BPC-157 consistently couples NO modulation with counteraction of free radical formation and oxidative stress, preventing peroxynitrite formation.
Section 03
Biological Pathways
- VEGFR2-Akt-eNOS axisAngiogenic signalling described in endothelial culture and rodent ischaemia models: raised VEGFR2 expression and internalisation, phosphorylation of Akt and eNOS, nitric oxide release and vasodilation.
- FAK-Paxillin adhesion signallingIn cultured tendon fibroblasts, dose-dependent phosphorylation of FAK and paxillin tracked with cell migration and with survival under oxidative stress. Causality was not tested directly.
- Growth hormone receptor and JAK-2Dose- and time-dependent rise in growth hormone receptor mRNA and protein in tendon fibroblasts; adding growth hormone then raised JAK2 phosphorylation. STAT proteins were never measured.
- MAPK/ERK1/2 cascadeDose-dependent ERK1/2 phosphorylation in endothelial cells, with induction of the immediate-early genes c-Fos, c-Jun and EGR-1. Blocking MEK abolished the proliferation and tube formation.
- EGR-1/NAB2 early responseIn an intestinal epithelial cell line, EGR-1 mRNA peaked at ~15 min and its co-repressor NAB2 at ~30 min. A self-limiting repair loop is proposed from this order, not demonstrated.
- Nitric oxide system interactionRaised eNOS and lowered iNOS mRNA were reported after rodent hippocampal ischaemia. Direction is not uniform: in a fistula model, faster healing came with lower eNOS expression.
- Src/Caveolin-1 signallingPhosphorylation of Src and caveolin-1 and dissociation of the eNOS-caveolin-1 complex in rat aortic rings and endothelial cells. Relaxation appeared only at high concentrations.
Section 04
Dosage Information
GEPPPGKPADDAGLV| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Subcutaneous | Self-administration outside any trial | 200–500 µg per day — roughly 2–7 µg/kg for a 70–90 kg adult; single doses near 1 mg are also reported | Circulating practice, not a finding. The range began as a 2016 blog conversion of a rat dose and was repeated until it sounded official. |
| Intramuscular | Self-administration outside any trial | 250–500 µg per day — roughly 3–7 µg/kg for a 70–90 kg adult | Same origin as the subcutaneous figures. Of a dose injected into muscle, 14–19% reached the blood in rats and 45–51% in dogs; in people, never measured. |
| Oral | Self-administration; rats drank it in water in the research | 200–1000 µg per day in practice, usually about 500 — roughly 2–14 µg/kg. Rats got 0.16 µg/mL in drinking water, about 12 mL a day each | How much survives the stomach has never been measured in a person, so the amount swallowed says nothing about what reaches the blood. |
| Intranasal | Self-administration outside any trial | 200–500 µg per day — roughly 2–7 µg/kg for a 70–90 kg adult | Experimental even inside that practice: nobody has measured how much is absorbed through the nose, in people or in animals. |
| Topical | Creams in practice; alkali skin burn in rats in research | Practice names no dose — only "twice daily as a cream". The rat study used a 200–800 ng/mL hydrogel, 0.5 mL on the wound twice a day | A gel concentration spread on an open burn in an animal, not a treatment regimen, and it cannot be converted into an amount of cream. |
| Intravenous | 2025 safety pilot — two healthy volunteers | 10 mg on day one, then 20 mg on day two — roughly 110–290 µg/kg for a 70–90 kg adult, the largest amounts ever given to a person | Two people, no control group, nothing measured but safety — and twenty to a hundred times what is injected subcutaneously in practice. |
Results
Syringe Fill Level (100u syringe)
Set positive values for: Recommended dose per kg.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Section 05
Protocols
- Protocol 01
Wolverine Stack - Injury Recovery
The most popular healing stack combining BPC-157 and TB-500 for comprehensive tissue repair. Ideal for tendon, ligament, and muscle injuries.
- Focus
- Healing & Recovery
- Level
- Intermediate
- Duration
- 4–8 weeks
- Protocol 02
BPC-157 Solo - Gut Health Protocol
BPC-157 oral protocol specifically for digestive issues, IBS, leaky gut, and intestinal inflammation.
- Focus
- Healing & Recovery
- Level
- Beginner
- Duration
- 4–8 weeks
- Protocol 03
Joint & Cartilage Recovery
Protocol combining BPC-157, TB-500, and collagen for joint pain, osteoarthritis, and cartilage repair.
- Focus
- Healing & Recovery
- Level
- Intermediate
- Duration
- 8–12 weeks
Section 06
Stability & Storage
Lyophilised powder
Kept sealed and away from moisture and light: up to 24 months or more at −20 °C, 6–12 months at 2–8 °C. Let the vial reach room temperature before opening, or condensation settles on the powder. It is usually reconstituted with bacteriostatic water.
After reconstitution
The solution is less stable and open to microbial contamination: keep it at 2–8 °C and use it within 21–28 days. For longer storage, split it into single-use aliquots and freeze at −20 °C. Repeated freeze-thaw cycles and vigorous shaking degrade the peptide.
Section 07
Side Effects & Precautions
BPC-157 has no established human safety profile. An absence of reported reactions in small or preclinical studies is not demonstrated safety.
How little human data exists
The entire published human record is about 30 people in three uncontrolled reports by one clinician: 17 treated for knee pain, 12 given a single bladder instillation, two given infusions. None was designed to detect harm, and no registered trial has posted results.
What the animal work does and does not show
In the animal toxicology that exists, BPC-157 was well tolerated: a 28-day study in rats and dogs found no changes attributable to the peptide. That base is thin — over 80% of the literature comes from one laboratory, no carcinogenicity study has ever been run, and none of it speaks to humans.
The commonly listed side effects are undocumented
Injection-site reactions, nausea, headache and dizziness circulate widely as this peptide's side effects. No peer-reviewed source records any of them in a person, and the mechanisms offered come from rat experiments. Nor is that a clean record: the human reports never monitored for adverse events.
Blood-vessel growth is the open question
BPC-157 promotes new blood-vessel growth, and that much is replicated in animals and in cultured human cells. What it means for someone with a tumour is unknown: tumour growth under BPC-157 has never been tested in a living animal, and the claim that it suppresses tumour blood supply has no source.
Groups and interactions nobody has studied
- Pregnancy, breastfeeding, children, older adults: no data of any kind.
- Impaired liver or kidney function: never studied.
- Other medicines: no interaction study exists in people, and whether BPC-157 affects drug-metabolising enzymes is unknown.
- Unapproved products: no pharmaceutical-grade BPC-157 exists anywhere, so concentration, purity and sterility rest on the seller's word.
Section 08
Regulatory Status
It remains an investigational compound: there is no approved label, indication, dose, pharmaceutical quality standard or established benefit-risk profile behind it.
FDA / United States
Not approved
BPC-157 was not on the 503A Bulks List as of 5 August 2026, and section 503A lets a pharmacy compound from a bulk substance only when it carries a USP/NF monograph, is a component of an approved drug or appears on that list — so no lawful compounding route is open. In 2023 the FDA had assigned it to Category 2 of the interim bulk-substances list, citing immunogenicity by some routes of administration and the difficulty of characterising peptide-related impurities.
FDA review
A committee has recommended easing
On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6 to add BPC-157 to the 503A Bulks List, against the written advice of the agency's own scientists. The vote does not bind the FDA: the list changes only through formal rulemaking, and that had not happened as of this check.
WADA
Prohibited under category S0
The ban covers every competing athlete at all times, in and out of competition; no therapeutic use exemption is granted, and a sanction can follow from evidence alone, without a positive sample.
U.S. Department of Defense
Off limits to service members
BPC-157 is on the Prohibited Dietary Supplement Ingredients List maintained under DoDI 6130.06 by the Operation Supplement Safety programme.
Australia
Prescription-only (Schedule 4)
The TGA entered BPC-157 into the Poisons Standard, so buying or holding it without a doctor's prescription is unlawful whatever a «research use only» label claims.
Clinical trials
No completed trial supports use
The phase II study in ulcerative colitis (PL 14736, Bepecin) stopped without full published results, and the phase I safety and pharmacokinetics study in healthy volunteers (NCT02637284) still carries «unknown» status with nothing published.
A «research use only» label does not turn a product into an approved medicine and says nothing about its purity. Regulatory status differs between jurisdictions and changes over time — check the current documents of your own regulator before relying on any of this.
We cover the 23–24 July 2026 vote of the FDA's Pharmacy Compounding Advisory Committee (PCAC) separately, in «The 2026 PCAC Peptide Vote» (/en/articles/fda-pcac-2026-peptides). In short: on 23 July the committee recommended adding BPC-157 to the 503A Bulks List — 8 votes to 6, against the written position of the FDA's own reviewers. The recommendation binds no one: the list changes only through formal rulemaking, which usually takes 8–12 months, and even a place on it would not make BPC-157 an approved medicine.
Section 09
Research Studies
- [1]Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulationHsieh MJ, Liu HT, Wang CN, et al. · Journal of Molecular Medicine · 2017
- [2]Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathwayHsieh MJ, Lee CH, Chueh HY, et al. · Scientific Reports · 2020
- [3]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationChang CH, Tsai WC, Lin MS, Hsu YH, Pang JH · Journal of Applied Physiology · 2011
- [4]Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblastsChang CH, Tsai WC, Hsu YH, Pang JH · Molecules · 2014
- [5]Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expressionTkalcević VI, Cuzić S, Brajsa K, et al. · European Journal of Pharmacology · 2007
- [6]Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitroHuang T, Zhang K, Sun L, et al. · Drug Design, Development and Therapy · 2015
- [7]Stable Gastric Pentadecapeptide BPC 157-NO-system RelationSikiric P, Seiwerth S, Rucman R, et al. · Current Pharmaceutical Design · 2014
- [8]Stable Gastric Pentadecapeptide BPC 157 and Wound HealingSeiwerth S, Milavic M, Vukojevic J, et al. · Frontiers in Pharmacology · 2021
- [9]Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the ratCerovecki T, Bojanic I, Brcic L, et al. · Journal of Orthopaedic Research · 2010
- [10]Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the FutureSikiric P, Hahm KB, Blagaic AB, et al. · Gut and Liver · 2020
Section 10
Frequently Asked Questions
In animals, repeatedly — tendon, gut, muscle and nerve injury models over two decades. In people it has never been tested in a controlled trial: the entire published human record is about 30 patients in three uncontrolled reports by one clinician, and no registered trial has posted results. So for humans there is no answer yet, only animal data and self-reports.
No human study has measured this. In rat tendon-healing experiments differences appear around day 14 to 21 of daily dosing. The timelines circulating online — two weeks for tendons, four for the gut — are extrapolations from that animal work plus user reports, not clinical observations.
Self-administration outside any trial runs at 200 to 500 µg a day subcutaneously or intramuscularly, roughly 2 to 7 µg/kg. That range is circulating practice rather than a research finding: it began as a 2016 blog conversion of a rat dose and was repeated until it sounded official. No human dose-finding study has ever been run.
Rats in the original experiments received it in drinking water and still showed gut healing, which is why oral products exist. But how much survives human digestion has never been measured, so a swallowed dose says nothing about what reaches the blood. Injection is not measured in people either — 14 to 19% of an intramuscular dose reached the blood in rats.
There is no established human safety profile. Injection-site reactions, nausea, headache and dizziness circulate widely as its side effects, yet no peer-reviewed source records any of them in a person — and that is not a clean record either, because the human reports never monitored for adverse events. The open question is blood-vessel growth: BPC-157 promotes it, and what that means for someone with a tumour has never been tested in a living animal.
No regulator anywhere has approved it for human use. WADA prohibits it under category S0 at all times, in and out of competition, with no therapeutic use exemption. In the United States it sits in Category 2 of the interim 503A list, so compounding pharmacies may not prepare it; in Australia it is prescription-only. A "research use only" label changes none of this.
The lyophilised powder does not strictly need it: sealed, dry and dark it keeps 6 to 12 months at 2–8 °C and 24 months or more at −20 °C. Once reconstituted it does — keep the solution at 2–8 °C and use it within 21 to 28 days, or freeze single-use aliquots. Repeated freeze-thaw cycles and vigorous shaking degrade the peptide.